{
    "nctId": "NCT03735680",
    "briefTitle": "A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer",
    "officialTitle": "A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety & Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Urothelial Carcinoma, Non-small Cell Lung Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Measure Mean Fluorescence Intensity of Histologically Confirmed Tumor vs Normal Tissue in Patients Undergoing Routine Surgery [Tumor to Background Ratio (TBR)]",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Biopsy-confirmed diagnosis of primary or recurrent respective tumor type and scheduled to undergo surgical resection\n* Part 1: Biopsy-confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC) or breast cancer\n* Part 2: Biopsy-confirmed diagnosis of HNSCC, breast cancer, colorectal cancer, prostate cancer, ovarian cancer, urothelial carcinoma and non-small cell lung cancer.\n* Part 3: Stage 2 to 4 HNSCC Including T0 or Tx unknown Primary cancers\n\nExclusion Criteria:\n\n* Histologically diagnosed by an excisional biopsy procedure\n* Tumors at sites of which the surgeon would assess that in vivo intraoperative imaging would not be feasible\n* Life expectancy \\<12 weeks\n* Hepatic impairment (Child-Pugh score \\>5) or significant liver disease including active hepatitis or cirrhosis",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}